Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Cash & Equivalents (2016 - 2025)

Biomerica's Cash & Equivalents history spans 16 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 7.21% year-over-year to $2.5 million; the TTM value through Nov 2025 reached $2.5 million, up 7.21%, while the annual FY2025 figure was $2.4 million, 42.47% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $2.5 million at Biomerica, down from $3.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $10.2 million in Q1 2022 and bottomed at $2.4 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $5.0 million (2021), against an average of $5.1 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 120.45% in 2021 before it tumbled 67.12% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $7.2 million in 2021, then fell by 29.62% to $5.1 million in 2022, then surged by 40.79% to $7.1 million in 2023, then crashed by 66.75% to $2.4 million in 2024, then increased by 7.21% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Cash & Equivalents are $2.5 million (Q4 2025), $3.1 million (Q3 2025), and $2.4 million (Q2 2025).